Disclosures: Naoto Kawabe: Nothing to Disclose, Teiji Kuzuya: Chugai Pharmaceutical Co: Speaking and Teaching, Eisai: Speaking and Teaching, Eli Lilly Japan: Speaking and Teaching, AstraZeneca: Speaking and Teaching, Yoshiki Hirooka: Nothing to Disclose 2614 SAFETY AND EFFICACY OF NAFAMOSTAT MESYLATE ANTICOAGULATION IN CENTRIFUGAL ARTIFICIAL LIVER SUPPORT SYSTEM FOR ALF AND ACLF PATIENTS AT HIGH RISK OF BLEEDING Zhu Xinfang 1 Bing-Yao Wang 1 Jian-Ming Zheng 1 Rong Xia 1 , 1 Huashan Hospital, Fudan University Background: Patients with acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) are consistently at high risk of bleeding and most exhibit decreased platelet levels, presenting a challenge for the conventional approach to artificial liver support systems (ALSS)
Life support medications were given to keep her heart pumping
However, from a pricing and product management standpoint, insurers may also want to consider behavioral responses and contract dynamics
But it's a real clue toward why one dose can echo for weeks after the trip ends
Best foods to support treatment Lean proteins (chicken breast, fish, egg whites, low-fat Greek yogurt, cottage cheese) should form the foundation of most meals
S., Rajakaruna, S., Saleh, Z., Abdelaziz, S
